These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38843859)

  • 1. Vimseltinib for tenosynovial giant cell tumour.
    Urakawa H; Imagama S
    Lancet; 2024 Jun; 403(10445):2665-2667. PubMed ID: 38843859
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
    Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
    Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Gelderblom H; Bhadri V; Stacchiotti S; Bauer S; Wagner AJ; van de Sande M; Bernthal NM; López Pousa A; Razak AA; Italiano A; Ahmed M; Le Cesne A; Tinoco G; Boye K; Martín-Broto J; Palmerini E; Tafuto S; Pratap S; Powers BC; Reichardt P; Casado Herráez A; Rutkowski P; Tait C; Zarins F; Harrow B; Sharma MG; Ruiz-Soto R; Sherman ML; Blay JY; Tap WD;
    Lancet; 2024 Jun; 403(10445):2709-2719. PubMed ID: 38843860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ⅲ. Novel Treatment Targeting CSF1-R for Tenosynovial Giant Cell Tumor].
    Takeuchi A; Tsuchiya H
    Gan To Kagaku Ryoho; 2022 Mar; 49(3):277-281. PubMed ID: 35299182
    [No Abstract]   [Full Text] [Related]  

  • 5. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenosynovial giant cell tumour of the hand in children under 10 years of age.
    Tsujino S; Matsumoto S; Ae K
    J Hand Surg Eur Vol; 2018 Mar; 43(3):335-337. PubMed ID: 29105587
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric Tenosynovial Giant Cell Tumor of the Flexor Hallucis Longus Tendon Sheath: A Case Report.
    Williams RD; Honeycutt MW; Manci EA; Nimityongskul P
    JBJS Case Connect; 2020; 10(2):e0519. PubMed ID: 32649117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenosynovial giant cell tumour of the finger: a case report.
    Jaiswal A; Ambade R
    Pan Afr Med J; 2023; 45():49. PubMed ID: 37575525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Cai W; Yang L; Li J; Li Q
    Asian J Surg; 2023 Dec; 46(12):6033-6034. PubMed ID: 37777406
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report.
    Geiger EJ; Jensen AR; Singh AS; Nelson SD; Bernthal NM
    J Orthop Sci; 2024 Jan; 29(1):458-462. PubMed ID: 36402606
    [No Abstract]   [Full Text] [Related]  

  • 15. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenosynovial Giant Cell Tumor in the Midfoot Treated With Femoral Head Allograft Reconstruction.
    Fuchs DJ; Switaj PJ; Peabody TD; Kadakia AR
    J Foot Ankle Surg; 2018; 57(1):172-178. PubMed ID: 28864387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
    Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
    BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.